Nasal Drug Delivery Market - Strategic Insights and Forecasts (2026-2031)

The Nasal Drug Delivery Market is forecast to grow at a CAGR of 6.4%, reaching USD 106.62 billion in 2031. This represents a significant increase from USD 78.20 billion in 2026, driven by expanding applications and strategic developments within the industry.

The market has evolved from a segment historically dominated by over-the-counter treatments for allergic rhinitis and congestion. It is now a diversified platform supporting systemic and localized therapeutic delivery, with its scope broadening into prescription and specialty therapeutics.

Increasing research and development focus on intranasal delivery pathways for CNS indications, such as migraine, epilepsy, and psychiatric therapies, is a primary driver. This emphasis is reshaping device design and formulation strategies, highlighting the route's potential for brain drug transport.

Strategic acquisitions and partnerships are consolidating proprietary nasal delivery technologies within larger pharmaceutical portfolios. This trend suggests a strategic move to integrate specialized nasal delivery systems into broader therapeutic offerings and enhance competitive positioning.

Updated pharmaceutical quality guidelines are significantly influencing manufacturing processes, quality control investments, and device precision requirements. Furthermore, manufacturers are increasingly approaching nasal products as unified delivery systems, integrating formulation science with delivery device engineering to improve outcomes.

The nasal drug delivery market faces technical challenges related to anatomical variability, mucociliary clearance, and limited residence time within the nasal cavity. These factors can affect drug absorption and necessitate innovative formulation and device solutions to ensure consistent therapeutic efficacy.